top of page
Spero Biopharma
![](https://static.wixstatic.com/media/c67711_ced9b8adf3504d489cef633c217afe0a~mv2.png/v1/fill/w_145,h_82,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/Image-empty-state.png)
Prevention and Treatment of Alzheimer's Disease
Company Name | Updating Date | Neurotech Category | Market Category | Target Market | Technologies | Company Founded Year | Company Number of Employees |
---|---|---|---|---|---|---|---|
Spero Biopharma | 02/07/2022 | NeuroPharmacology | NeuroBioTechnology | Biotechnology & Biopharmaceutical | Medical use (pharma, nerve damage rehabilitation, neurodiagnostics. inc. early diagnosis) | Biochemical: pharmacological drugs (Developing drugs) | 01/01/2019 | "1-10" |
Spero Biopharma is the developer of Ladostigil, a drug designed to treat mild cognitive impairment before it progresses to Alzheimer's disease.
bottom of page